Highlights Newsletter 4

This newsletter presents you the following key sessions:

1. Podcast with Prof. John N. Allan (Weill Cornell Medicine, New York) about the updated results of the
    CAPTIVATE trial

2. Real-world data show superior efficacy of Axicabtagene Ciloleucel compared to chemoimmunotherapy
    in elderly patients with relapsed/refractory Large B-Cell Lymphoma after ≥2 lines of prior therapy

3. Intensive remission induction chemotherapy prior to allogeneic haematopoietic cell transplantation does not
    confer survival advantage in R/R AML

4. Deep and rapid responses with a dexamethasone-sparing combination of daratumumab and lenalidomide in
    elderly patients with multiple myeloma

5. Blinatumomab with consolidation chemotherapy prolongs the overall survival of patients with MRD-negative
    B-Cell ALL